ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Cross-Platform Biosensing of Immune Receptors Using Peptide-Functionalized Graphene.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Selective and Fast Cortisol Sensing in Human Saliva Using Graphene-Based On-Chip Field-Effect Transistors.Small science · 2026Article
- Graphene Triggers Inflammation in Murine Microglia via Phagocytosis.Small science · 2026Article
- Nano-Enabled Microfluidic Platforms for Functional Immunomonitoring in Pediatric Sepsis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Changes in the composition of specific cell-surface molecules on immune cells are important early markers of directed immune responses. Current biosensors largely focus on detecting soluble disease markers. Here, a peptide-functionalized graphene biosensor is presented capable of platform-independent, highly sensitive detection of specific immune receptors on living cells. Formyl peptide receptor 2 (FPR2) is targeted, a key modulator of innate immune cells, and validated the technology in two complementary formats: i) graphene-enhanced surface plasmon resonance (SPR) as a robust optical benchmark, and ii) graphene field-effect transistors (gFETs) as a compact, cost-effective electrical alternative. Target specificity is first confirmed using HEK293T cells selectively overexpressing FPR2. Detection of FPR2 on primary human neutrophils is achieved with high reproducibility using fewer than 10 000 cells mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.